Background: Increasingly alarmed by the health risks (that is, weight gain, elevated lipids, and poor glucose tolerance) posed by novel antipsychotic medications, clinicians who treat schizophrenia are attempting to help patients improve lifestyle factors. Unfortunately, schizophrenia research has neglected exercise as a legitimate adjunctive treatment for schizophrenia.
H ealth professionals accept exercise as an important contributor to weight control and health maintenance for most medical disorders (1) (2) (3) . Yet, surprisingly, schizophrenia research has ignored the role of exercise as a legitimate adjunctive treatment for schizophrenia. A Medline search revealed few studies that examine exercise among schizophrenia patients. One study by Greenberg and others engaged subjects in stepped weight-control interventions (4) . The studied strategies included exercise, diet, and behavioural modification, as well as treatment with sibutramine, orlistat, vertical banded gastroplasty, and Roux-en-Y surgical procedures. This study reported some success with stepped approaches but did not differentiate the benefits of exercise from other strategies. In summary, we need studies that focus on exercise interventions, especially because we know antipsychotic medications cause weight gain (5-7).
Wirshing and others compared weight gain liabilities among men with schizophrenia receiving 5 different drug treatments: clozapine, olanzapine, risperidone, haloperidol, and sertindole (8) . They found that olanzapine and clozapine caused the most weight gain. Over 30% of individuals who were treated with olanzapine gained more than 10% of their original weight (9) .
Increased body weight and obesity are major causes of many chronic diseases, such as hypertension, cardiovascular disease, and diabetes mellitus (10, 8) . Substantial weight gain may adversely affect self-esteem, social functioning, and physical activity (9) . Antipsychotic-induced weight gain is a common cause of noncompliance and discontinuance of treatment, resulting in the return of psychotic symptoms (11) . Novel antipsychotic medications commonly cause elevated cholesterol, triglycerides, and blood sugars (12) . The health risks from antipsychotic-induced weight gain pose many challenges for psychiatrists, who must weigh the risks and benefits of novel antipsychotic medications.
These issues concern patients, their families, and their clinicians. Unfortunately, clinicians lack a body of literature to draw from to help prevent weight gain. To protect against weight gain, health professionals often suggest that patients obtain memberships at local fitness facilities. We decided to study the feasibility of this approach.
Purpose of Study
This small pilot study explored whether patients with schizophrenia would exercise if given access to a local Young Men's Christian Association (YMCA). To what extent would schizophrenia patients adhere to an exercise program if offered access to a fitness facility?
Study Design
This is a prospective, nonblind pilot study of outpatients with a psychotic disorder who were treated with olanzapine. Ethics approval was obtained, and all participants provided informed consent prior to entering the study.
Patients were recruited from the Psychotic Disorders Clinic, Hamilton Health Sciences, McMaster Hospital site, in Hamilton, Ontario, or from the Hamilton Program for Schizophrenia. Patients were excluded if they had comorbid illness for eating disorder, substance abuse and (or) dependence, or bipolar disorder. Eligible participants met the following criteria: DSM-IV criteria for schizophrenia or schizoaffective disorder, between age 16 and 55 years, on a stable dose of olanzapine for at least 4 weeks, and stable in the clinical judgment of the principal investigator. Table 3 Reasons for poor attendance (YMCA group)
Reasons given for not attending
Percentage of subjects reporting (n = 10)
Moved 10
Low comfort level 20
Lack of motivation 60
Relapse of illness 10
No one to go with 20
Medication change 10
Hospitalization 10
A total of 50 subjects were approached to enter the study. Of the subjects, 20 were randomized, and 10 received YMCA passes based on the random allocation. The treating physician determined the dosage of olanzapine used, based on clinical judgment. The study period lasted 6 months.
The intervention included a free membership to the YMCA for 6 months. This group met with a YMCA physical activity coach who conducted a fitness assessment of their cardiovascular endurance and musculoskeletal strength to prescribe an appropriate exercise program. The YMCA physical activity assessment comprised muscular strength tests, push-ups, sit-ups, flexibility, heart-rate monitoring, and 3 walking tests of 6 minutes each. The exercise facility offered a pool, aerobics classes, a weight room, a treadmill, racquetball, a tennis court, a track, and a basketball court. All subjects received information about diet, exercise, and health. To improve access, researchers provided parking vouchers and bus tickets.
The research nurse collected data at baseline and endpoint (6 months plus or minus 2 months). The information that was collected included weight, body mass index (BMI), adherence to exercise program, and reasons and date of every withdrawal from the study for YMCA subjects. The nurse also reviewed Canada's exercise and food guide with all subjects. Table 1 contains the full demographic information that was available for the 10 subjects.
Results

Subjects
For YMCA subjects, the mean dosage of olanzapine was 11.5 mg daily. Table 2 outlines the results of the baseline physical assessment. The baseline resting blood pressure, heart rate, and respiration rate were within normal limits. The BMI, however, was outside the normal range at baseline. The mean percentage body fat and the mean waist circumference were outside the normal range at baseline for the YMCA group. All subjects complained of weight gain prior to entering the study. Subjects started olanzapine between November 1996 and April 2000. The average weight gain between the start of olanzapine and the study was 18.9 kg for 9 out of 10 subjects, based on retrospective chart review.
Attendance
Attendance was defined as a 30-minute session at the YMCA 3 times weekly, or 12 times in a month. Of the 10 YMCA subjects, only 1 subject (subject 5) met criteria for full attendance for each of the 6 months. Subject 2 attended 3 of the 6 months. Of the 10 subjects, 2 did not attend at all. Figure 1 provides the information on attendance at YMCA for each subject.
Dropout rates for attendance at the YMCA were 90% at 6 months, 70% at 5 months, and 40% at 4 months. The main reason that the subjects gave for poor attendance was lack of motivation (Table 3) Weight At baseline, the mean weight gain was 2 kg for the YMCA group. At endpoint, data were available for 8 of the 10 subjects. Subject 5 who had complete attendance for 6 months lost 15 kg. The most common BMI category at endpoint was obese (greater than 30).
Discussion
Methodological problems with this study included a small sample size, no blinding for the subjects, and lack of a control sample. A more scientifically rigorous study is necessary to determine whether we can attribute weight loss to regular exercise.
Nevertheless, the poor YMCA attendance provides us with valuable clues about barriers to exercise in this population. Most subjects dropped out of the exercise program, despite access to the YMCA. The main reason that was given was a lack of motivation. In the general population, dropout rates for exercise range from 20% to 80% (13). Thus, we should expect that a population with psychosis, dealing with challenges that are not faced by the general population, might have worse rates.
One subject who exercised regularly at the YMCA lost 15 kg. Thus, the results suggest that there is a potential for exercise to induce weight loss among this population.
The weight increases suggest that clinicians should monitor diet, exercise, and weight gain in patients treated with olanzapine and other antipsychotic medications. It is imperative that research develop effective interventions to help our patients include exercise while taking these medications.
In future studies, researchers should consider strategies to increase motivation for exercise. These strategies might include groups, personal trainers, rewards, or a buddy system. Future research should consider the role of treating the negative syndrome to enhance motivation for physical activity. The Stages of Change Model or the Transtheoretical Model (14) may help identify patients who may be ready to adopt regular exercise as part of their daily lives. Finally, researchers need to facilitate developing diet and exercise interventions that address weight gain from atypical antipsychotic medications and that consider the unique challenges faced by this population. 
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